The Trump administration is nearing deals with drugmakers Eli Lilly and Novo Nordisk to offer some of their obesity drugs to consumers for as low as $149 per month, according to two people familiar ...

The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.

Overview AI SaaS market globally is expected to exceed $101.7 billion in 2025, with nearly 40% annual growth. Major players ...

Healthy people who suffer traumatic spinal injuries are at significantly greater risk for long-term chronic health conditions ...

Pfizer and Novo Nordisk continue to fight for ownership of obesity startup Metsera; CDER Director George Tidmarsh leaves his ...